Skip to content Skip to footer
Subscribe Now

NEWS

iHealthScreen Reports FDA Clearance of iPredict-DR for Diabetic Retinopathy Screening
Shots: The US FDA has granted 510(k) clearance to iPredict-DR, an AI-powered software that automatically detects more than mild diabetic retinopathy (mtmDR) in adults with diabetes who have not been previously diagnosed iPredict-DR uses AI to analyze retinal fundus images from the iCare DRSplus camera for non-invasive & affordable diabetic retinopathy screening, with clearance backed…
July 9, 2026
AstraZeneca Inks $1.9B Exclusive Licensing Deal with Sino Biopharmaceutical for TQC3721
Shots: Sino Biopharmaceutical has entered into an exclusive license agreement with AstraZeneca for the development, manufacturing & commercialization of TQC3721, an inhaled PDE3/4 inhibitor As per the deal, AstraZeneca secured exclusive rights to develop, manufacture, & commercialize TQC3721 outside China, along with exclusive global rights to select future development programs In return, Sino will receive…
July 9, 2026
Biocytogen Collaborates with Whitehawk Therapeutics to Develop Bispecific ADC
Shots: Biocytogen has entered into a global collaboration with Whitehawk Therapeutics to develop bispecific antibody-drug conjugates (BsADCs) Biocytogen will provide ~5 bispecific antibodies from its RenLite platform & Whitehawk will evaluate these in combination with its ADC linker-payload technologies, with Whitehawk holding the option to advance resulting BsADC candidates Biocytogen will receive an upfront payment,…
July 8, 2026
Longeviti Launches ClearFit AI Platform for Bedside Brain Ultrasound Access
Shots: Longeviti Neuro has launched ClearFit AI, a Brain Ultrasound Interface, creating a persistent acoustic window to the brain to enable real-time bedside ultrasound imaging after neurosurgery ClearFit AI combines sonolucent cranial implants, ultrasound compatibility, clinical workflow support, & AI-enhanced imaging to enable bedside brain assessment within existing neuro care workflows, potentially reducing CT/MRI transport…
July 8, 2026
OTR Therapeutics Partners with LG Chem to Develop Novel Oncology Therapies
Shots: OTR has partnered with LG Chem to identify, evaluate & develop novel oncology assets from China, leveraging OTR's R&D platform & LG Chem's global development expertise & commercial infrastructure As per the deal, OTR will identify & advance oncology assets through early clinical development in China, while LG Chem will jointly evaluate & license…
July 8, 2026
Splash Licenses Argent BioPharma’s CannEpil for Global Epilepsy Rights
Shots: Splash secured exclusive global rights to develop & commercialize CannEpil for drug-resistant epilepsy, refractory epilepsy, seizure disorders, & related neurological conditions, incl. future product improvements & next-generation formulations Splash secured a $1M strategic investment from C/M Capital Partners, while Mercer Street forgave ~$5M in Argent BioPharma debt and Splash issued $5.5M in preferred equity…
July 7, 2026
Load more